CEO, William V. Williams, Reveals Game-Changing Partnership and Innovative Breakthroughs in Targeted Immunotherapies for Cancer Treatment
NEW YORK, NY - (NewMediaWire) - May 30, 2023 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company focused on targeted immunotherapies for cancer, is pleased to announce that its President and CEO, William V. Williams, recently conducted an interview with SmallCapsDaily. During the interview, Mr. Williams discussed BriaCell's exciting and recent collaboration with Prevail Partners and Prevail Infoworks, as well as the Company's innovative strategy for cancer treatment.
All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security. All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.
(NewMediaWire) - May 30, 2023 - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology company focused on targeted immunotherapies for cancer, is pleased to announce that its President and CEO, William V. Williams, recently conducted an interview with SmallCapsDaily. During the interview, Mr. Williams discussed BriaCell's exciting and recent collaboration with Prevail Partners and Prevail Infoworks, as well as the Company's innovative strategy for cancer treatment.
